These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34464909)

  • 1. Retrospective analysis (2009-2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India.
    Kamalraj N; Sathishkumar M; Arunvignesh M; Baskar V; Jebarani S; Amutha A; Deepa M; Shanthi Rani CS; Chandru S; Unnikrishnan R; Anjana RM; Harish M; Mohan V
    Diabetes Metab Syndr; 2021; 15(5):102261. PubMed ID: 34464909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Hour Postload Hyperglycemia Confers Higher Risk of Hepatic Steatosis to HbA1c-Defined Prediabetic Subjects.
    Fiorentino TV; Andreozzi F; Mannino GC; Pedace E; Perticone M; Sciacqua A; Perticone F; Sesti G
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4030-4038. PubMed ID: 27459528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes.
    Calanna S; Scicali R; Di Pino A; Knop FK; Piro S; Rabuazzo AM; Purrello F
    Nutr Metab Cardiovasc Dis; 2014 Jun; 24(6):670-6. PubMed ID: 24656139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risks of different grades of non-alcoholic fatty liver disease in prediabetic subjects with impaired fasting glucose and glucose tolerance, including the isolated glycosylated hemoglobin levels of 5.7-6.4% in a Chinese population.
    Li CH; Chou YT; Shen WC; Lu FH; Yang YC; Wu JS; Chang CJ
    J Diabetes Investig; 2020 Sep; 11(5):1336-1343. PubMed ID: 32270583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study.
    Pereira ENGDS; Paula DP; de Araujo BP; da Fonseca MJM; Diniz MFHS; Daliry A; Griep RH
    World J Gastroenterol; 2021 Aug; 27(29):4913-4928. PubMed ID: 34447235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter.
    Chon YE; Kim KJ; Jung KS; Kim SU; Park JY; Kim do Y; Ahn SH; Chon CY; Chung JB; Park KH; Bae JC; Han KH
    Yonsei Med J; 2016 Jul; 57(4):885-92. PubMed ID: 27189281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes.
    Banitalebi E; Faramarzi M; Nasiri S; Mardaniyan M; Rabiee V
    Clin Mol Hepatol; 2019 Sep; 25(3):294-304. PubMed ID: 31142104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease.
    Vanjiappan S; Hamide A; Ananthakrishnan R; Periyasamy SG; Mehalingam V
    Diabetes Metab Syndr; 2018 Jul; 12(4):479-482. PubMed ID: 29402657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes.
    Wang C; Cai Z; Deng X; Li H; Zhao Z; Guo C; Zhang P; Li L; Gu T; Yang L; Zhao L; Wang D; Yuan G
    Int J Med Sci; 2021; 18(14):3280-3289. PubMed ID: 34400897
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes.
    El-Ashmawy HM; Ahmed AM
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):859-864. PubMed ID: 30601337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver hemodynamic patterns in nonalcoholic steatosis: Doppler ultrasonography and histological evaluation.
    Gonçalves Dos Reis Monteiro ML; Ferreira De Almeida E Borges V; Machado De Alcântara T; Borges De Araújo L; De Fátima Pinheiro C; Lemos Debs Diniz A
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):19-29. PubMed ID: 26887796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
    Shao N; Kuang HY; Hao M; Gao XY; Lin WJ; Zou W
    Diabetes Metab Res Rev; 2014 Sep; 30(6):521-9. PubMed ID: 24823873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Ferritin level, microalbuminuria and non-alcoholic fatty liver disease in type 2 diabetic patients.
    Amin RF; El Bendary AS; Ezzat SE; Mohamed WS
    Diabetes Metab Syndr; 2019; 13(3):2226-2229. PubMed ID: 31235161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Subgroups and Chronic Complications of Diabetes in Middle-Aged and Elderly Chinese:A Prospective Cohort Study.
    Wang F; Zheng R; Li L; Xu M; Lu J; Zhao Z; Li M; Wang T; Wang S; Bi Y; Xu Y; Ning G; Cai W
    Front Endocrinol (Lausanne); 2021; 12():802114. PubMed ID: 35154005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults.
    Guo W; Lu J; Qin P; Li X; Zhu W; Wu J; Xu N; Zhang Q
    Lipids Health Dis; 2020 Oct; 19(1):218. PubMed ID: 33028338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic Fat in Participants With and Without Incident Diabetes in the Diabetes Prevention Program Outcome Study.
    Goldberg RB; Tripputi MT; Boyko EJ; Budoff M; Chen ZZ; Clark JM; Dabelea DM; Edelstein SL; Gerszten RE; Horton E; Mather KJ; Perreault L; Temprosa M; Wallia A; Watson K; Irfan Z
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4746-e4765. PubMed ID: 33705543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes.
    Fennoun H; Mansouri SE; Tahiri M; Haraj NE; Aziz SE; Hadad F; Hliwa W; Badr W; Chadli A
    Pan Afr Med J; 2020; 37():270. PubMed ID: 33598084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of fetuin-A are associated with moderate-severe hepatic steatosis in young adults.
    Filardi T; Panimolle F; Tiberti C; Crescioli C; Lenzi A; Pallotta N; Morano S
    J Endocrinol Invest; 2021 Jan; 44(1):105-110. PubMed ID: 32350824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.